Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial
Tóm tắt
Từ khóa
Tài liệu tham khảo
Johnell, 2004, An estimate of the worldwide prevalence, mortality and disability associated with hip fracture, Osteoporos Int, 15, 897, 10.1007/s00198-004-1627-0
Johnell, 2006, An estimate of the worldwide prevalence and disability associated with osteoporotic fractures, Osteoporos Int, 17, 1726, 10.1007/s00198-006-0172-4
Whitaker, 2012, Bisphosphonates for osteoporosis—where do we go from here?, N Engl J Med, 366, 2048, 10.1056/NEJMp1202619
Black, 2012, Continuing bisphosphonate treatment for osteoporosis–for whom and for how long?, N Engl J Med, 366, 2051, 10.1056/NEJMp1202623
Crandall, 2014, Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review, Ann Intern Med, 161, 711, 10.7326/M14-0317
Leder, 2009, Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis, J Clin Endocrinol Metab, 94, 2915, 10.1210/jc.2008-2630
Miller, 2008, Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial, Bone, 43, 222, 10.1016/j.bone.2008.04.007
Leder, 2014, Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial, J Clin Endocrinol Metab, 99, 1694, 10.1210/jc.2013-4440
Tsai, 2013, Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial, Lancet, 382, 50, 10.1016/S0140-6736(13)60856-9
Cosman, 2011, Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis, J Bone Miner Res, 26, 503, 10.1002/jbmr.238
Black, 2003, The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis, N Engl J Med, 349, 1207, 10.1056/NEJMoa031975
Finkelstein, 2010, Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis, J Clin Endocrinol Metab, 95, 1838, 10.1210/jc.2009-1703
Black, 2001, An assessment tool for predicting fracture risk in postmenopausal women, Osteoporos Int, 12, 519, 10.1007/s001980170072
Ensrud, 2004, Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension, J Bone Miner Res, 19, 1259, 10.1359/JBMR.040326
Sorensen, 2003, Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience, Bone, 32, 120, 10.1016/S8756-3282(02)00946-8
Black, 2012, The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT), J Bone Miner Res, 27, 243, 10.1002/jbmr.1494
Papapoulos, 2012, Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension, J Bone Miner Res, 27, 694, 10.1002/jbmr.1479
Cosman, 2009, Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent, J Clin Endocrinol Metab, 94, 3772, 10.1210/jc.2008-2719
Ettinger, 2004, Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate, J Bone Miner Res, 19, 745, 10.1359/jbmr.040117
Eastell, 2009, Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS), J Bone Miner Res, 24, 726, 10.1359/jbmr.081215
Obermayer-Pietsch, 2008, Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment, J Bone Miner Res, 23, 1591, 10.1359/jbmr.080506
Boonen, 2008, Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis, J Clin Endocrinol Metab, 93, 852, 10.1210/jc.2007-0711
Miller, 2008, Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate, J Clin Endocrinol Metab, 93, 3785, 10.1210/jc.2008-0353
Nancollas, 2006, Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite, Bone, 38, 617, 10.1016/j.bone.2005.05.003
Black, 2005, One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis, N Engl J Med, 353, 555, 10.1056/NEJMoa050336
Rittmaster, 2000, Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate, J Clin Endocrinol Metab, 85, 2129
Bala, 2014, Cortical porosity identifies women with osteopenia at increased risk for forearm fractures, J Bone Miner Res, 29, 1356, 10.1002/jbmr.2167
Chen, 2006, Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis, J Bone Miner Res, 21, 1785, 10.1359/jbmr.060802
Austin, 2012, Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures, J Bone Miner Res, 27, 687, 10.1002/jbmr.1472
Vasikaran, 2011, Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards, Osteoporos Int, 22, 391, 10.1007/s00198-010-1501-1
Sornay-Rendu, 2005, Rate of forearm bone loss is associated with an increased risk of fracture independently of bone mass in postmenopausal women: the OFELY study, J Bone Miner Res, 20, 1929, 10.1359/JBMR.050704
Berger, 2009, Association between change in BMD and fragility fracture in women and men, J Bone Miner Res, 24, 361, 10.1359/jbmr.081004
Nguyen, 2005, Femoral neck bone loss predicts fracture risk independent of baseline BMD, J Bone Miner Res, 20, 1195, 10.1359/JBMR.050215
Garnero, 2000, Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study, J Bone Miner Res, 15, 1526, 10.1359/jbmr.2000.15.8.1526